NCI-H69/CPR
[Create a profile and sign in to view pricing and add to cart]
- Description
- Ask a Question
Description
Description: NCI-H69/CPR is a drug resistant subline of NCI-H69 (ECACC catalogue no. 91091802). Drug resistance was developed by addition of a stepwise increase in cisplatin to the growth medium of the parental line. The cell line exhibits a 5-fold resistance to cisplatin and is cross resistant to melphalan. A significant change in cellular glutathione content or sensitivity to cadmium chloride (as indicator of metallothionein content) was not detected, but changes in glutathione-S-transferase activity were seen. Cisplatin accumulation was unchanged compared with the parent line. It is recommended to culture the cells without drugs after resuscitation until the first passage.
Also Known As:
Species: Human
Tissue: Lung
Growth Properties: Aggregates in suspension
Morphology:
Growth Medium: RPMI 1640 + 2mM Glutamine + 0.4µg/ml cisplatin + 10% Foetal Bovine Serum (FBS).
Subculturing Procedure: Maintain cultures between 3-9 x 100,000 cells/ml; 5% CO2; 37°C; resuscitate in drug-free medium until first passage.
Release Conditions: No
Depositor: Dr P Twentyman, Dr. K. Wright, UKCCR, PO Box 123, Lincolns Inn Fields, London WC2A 3PX
Originator: Yes
References: Br J Cancer 1992;65:684, Cancer Res 1992;52:5674
Hyperlink to ECACC Cell Line Data Sheet: 96042328
Ask a Question
Have a question about this product? Our technical team is here to help.
